Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that coat damage in captive rhesus macaques is unlikely caused by parasitic, bacterial, or mycotic infections but may be linked to environmental or behavioral factors affecting hair growth.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

In this study, both physician and patient reports revealed that more severe alopecia areata was associated with higher emotional symptoms and greater activity limitations among patients.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

In this study, researchers found that activating RORA in hair follicle stem cells reduced the expression of cytoskeleton-related genes, affecting cell migration and adhesion, which may aid in understanding hair follicle development and potentially inform alopecia treatments.

In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.

In this phase 2b/3 trial, ritlecitinib showed effectiveness in treating alopecia areata patients with varying hair loss profiles, significantly improving patient-reported outcomes for hair regrowth and satisfaction compared to placebo, regardless of the hair loss type and extent at baseline.

This study found that 45.5% of alopecia areata patients treated with ritlecitinib 50 mg daily achieved significant hair regrowth, with most maintaining their response over 24 months.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.

This study found that 60% of examined prostate tumors had new somatic substitutions in the SRD5A2 gene, affecting enzyme activity and potentially influencing prostate cancer progression.

In this study, researchers developed a near-infrared-responsive nanoplatform that synergistically enhances chronic wound healing by accelerating mitochondrial restoration and immune modulation, leading to enhanced wound repair and high-quality healing in diabetic rat models.

This study suggests that dsRNA may enhance KRT9 expression in palm and sole skin through β-catenin signaling, potentially linking mechanical damage to specific skin features and certain skin conditions.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.

This study found that RXRα/RARγ heterodimers are necessary for retinoic acid-induced keratinocyte proliferation in the skin, while normal epidermal maintenance does not require RAR-mediated signaling.

This study examined 27 DRESS patients diagnosed in Thailand, identifying phenytoin, allopurinol, and nevirapine as common causes, with a 3.7% mortality rate and systemic corticosteroids being a common treatment.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

In this animal study, finasteride exposure led to impaired spermatogenesis in rats, while the novel compound DA-9401, derived from three medicinal herbs, demonstrated potential in improving sperm parameters and reducing testicular apoptosis when used alone or with finasteride.

This review summarizes the role of Ectodysplasin A signaling in skin appendage development and various diseases, noting potential clinical applications but reporting no new research findings.

This study reports no new findings but provides corrected figures for the long-term safety and efficacy of ritlecitinib in treating alopecia areata from the ALLEGRO-LT phase 3 study.

This study concludes that rhesus macaques are a suitable model for testing the pharmacological properties of finasteride and other 5aR inhibitors, due to their biochemical similarity to humans.

In this study, researchers reported that the Pinkie mutation in mice, affecting RXRa activity, leads to skewed Th1 development and suggests RXRa's role in Th2 differentiation, impacting immune responses.

This case study reports on a rare form of vitamin D resistant rickets in a 37-year-old male, highlighting the condition's clinical features and the necessity for a thorough understanding of calcium and vitamin D metabolism in the diagnosis and management of metabolic bone diseases.